218 related articles for article (PubMed ID: 37075952)
21. Systematic in vitro nanotoxicity study on anodic alumina nanotubes with engineered aspect ratio: understanding nanotoxicity by a nanomaterial model.
Wang Y; Kaur G; Zysk A; Liapis V; Hay S; Santos A; Losic D; Evdokiou A
Biomaterials; 2015 Apr; 46():117-30. PubMed ID: 25678121
[TBL] [Abstract][Full Text] [Related]
22. Lysosome-dependent cell death and deregulated autophagy induced by amine-modified polystyrene nanoparticles.
Wang F; Salvati A; Boya P
Open Biol; 2018 Apr; 8(4):. PubMed ID: 29643148
[TBL] [Abstract][Full Text] [Related]
23. Designing polymer conjugates as lysosomotropic nanomedicines.
Duncan R
Biochem Soc Trans; 2007 Feb; 35(Pt 1):56-60. PubMed ID: 17233601
[TBL] [Abstract][Full Text] [Related]
24. Safety of Nanoparticles in Medicine.
Wolfram J; Zhu M; Yang Y; Shen J; Gentile E; Paolino D; Fresta M; Nie G; Chen C; Shen H; Ferrari M; Zhao Y
Curr Drug Targets; 2015; 16(14):1671-81. PubMed ID: 26601723
[TBL] [Abstract][Full Text] [Related]
25. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity.
Stern ST; Adiseshaiah PP; Crist RM
Part Fibre Toxicol; 2012 Jun; 9():20. PubMed ID: 22697169
[TBL] [Abstract][Full Text] [Related]
26. Exploiting endocytosis for nanomedicines.
Akinc A; Battaglia G
Cold Spring Harb Perspect Biol; 2013 Nov; 5(11):a016980. PubMed ID: 24186069
[TBL] [Abstract][Full Text] [Related]
27. Physiological determinants and plausible '6R' roadmap for clinical success of nanomedicines.
Shahiwala A
Nanomedicine (Lond); 2023 Aug; 18(18):1207-1222. PubMed ID: 37650539
[TBL] [Abstract][Full Text] [Related]
28. The nanomedicines alliance: an industry perspective on nanomedicines.
Malinoski FJ
Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic nanostructures and nanotoxicity.
Sarma A; Bania R; Devi JR; Deka S
J Appl Toxicol; 2021 Oct; 41(10):1494-1517. PubMed ID: 33641187
[TBL] [Abstract][Full Text] [Related]
30. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
Muthu MS; Singh S
Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
[TBL] [Abstract][Full Text] [Related]
31. Critical considerations for targeting colorectal liver metastases with nanotechnology.
Arshad U; Sutton PA; Ashford MB; Treacher KE; Liptrott NJ; Rannard SP; Goldring CE; Owen A
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1588. PubMed ID: 31566913
[TBL] [Abstract][Full Text] [Related]
32. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
[TBL] [Abstract][Full Text] [Related]
33. Purification processes of polymeric nanoparticles: How to improve their clinical translation?
Tehrani SF; Bharadwaj P; Leblond Chain J; Roullin VG
J Control Release; 2023 Aug; 360():591-612. PubMed ID: 37422123
[TBL] [Abstract][Full Text] [Related]
34. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
35. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
Chen Z; Zheng Y; Shi Y; Cui Z
Int J Nanomedicine; 2018; 13():319-336. PubMed ID: 29391792
[TBL] [Abstract][Full Text] [Related]
36. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
[TBL] [Abstract][Full Text] [Related]
37. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine.
Donahue ND; Acar H; Wilhelm S
Adv Drug Deliv Rev; 2019 Mar; 143():68-96. PubMed ID: 31022434
[TBL] [Abstract][Full Text] [Related]
38. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
39. Roadmap and strategy for overcoming infusion reactions to nanomedicines.
Szebeni J; Simberg D; González-Fernández Á; Barenholz Y; Dobrovolskaia MA
Nat Nanotechnol; 2018 Dec; 13(12):1100-1108. PubMed ID: 30348955
[TBL] [Abstract][Full Text] [Related]
40. Medical and dental applications of nanomedicines.
Kavoosi F; Modaresi F; Sanaei M; Rezaei Z
APMIS; 2018 Oct; 126(10):795-803. PubMed ID: 30264432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
